Avalo Therapeutics (NASDAQ:AVTX) Earns Buy Rating from BTIG Research

Avalo Therapeutics (NASDAQ:AVTX)‘s stock had its “buy” rating reiterated by BTIG Research in a report issued on Tuesday,Benzinga reports. They presently have a $40.00 target price on the stock. BTIG Research’s price objective indicates a potential upside of 196.30% from the stock’s current price.

AVTX has been the topic of a number of other research reports. Guggenheim assumed coverage on Avalo Therapeutics in a report on Monday, February 2nd. They set a “buy” rating and a $50.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Avalo Therapeutics in a research note on Friday, January 9th. Mizuho raised Avalo Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. Finally, HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of Avalo Therapeutics in a research note on Thursday, January 15th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Avalo Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $35.50.

Avalo Therapeutics Price Performance

Shares of NASDAQ:AVTX opened at $13.50 on Tuesday. Avalo Therapeutics has a 1-year low of $3.39 and a 1-year high of $20.72. The stock has a market cap of $249.89 million, a P/E ratio of -2.52 and a beta of 0.84. The firm has a fifty day moving average price of $15.65 and a 200 day moving average price of $15.77.

Insider Buying and Selling at Avalo Therapeutics

In related news, insider Mittie Doyle sold 25,492 shares of the company’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $16.15, for a total transaction of $411,695.80. Following the transaction, the insider owned 3,622 shares of the company’s stock, valued at $58,495.30. This represents a 87.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.25% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Avalo Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BIT Capital GmbH acquired a new position in shares of Avalo Therapeutics during the 3rd quarter worth $25,000. PFS Partners LLC lifted its stake in shares of Avalo Therapeutics by 100.0% in the fourth quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock valued at $36,000 after purchasing an additional 1,000 shares during the period. Quadrature Capital Ltd purchased a new stake in Avalo Therapeutics during the second quarter worth about $55,000. Boothbay Fund Management LLC acquired a new position in Avalo Therapeutics during the second quarter worth about $56,000. Finally, Dimensional Fund Advisors LP purchased a new position in Avalo Therapeutics in the third quarter valued at about $143,000. Institutional investors and hedge funds own 87.06% of the company’s stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.